Navigation Links
New Findings in Fragile X Mental Retardation Protein

Researchers in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale School of Medicine have done crucial progress in understanding Fragile X mental retardation protein (FMRP), laying the groundwork for possible new treatments for Fragile X syndrome(FXS).

Fragile X syndrome, the leading inherited form of mental retardation is mainly caused by a mutation in the FMR1 gene on the X chromosome, leading to the loss of FMRP, which is abundantly expressed in the brain and testes. Without this protein, brain development is hampered and nerve cells cannot communicate with each other appropriately, resulting in the reduced ability to learn and memorize.

Fragile X syndrome affects about one in 4,000 males and one in 8,000 females. About 20 percent of children with FXS have autism and about five percent of autistic children have FXS. The research team led by Yingqun Huang, M.D., assistant professor in Yale Ob/Gyn, previously found that FMRP interacts with a nuclear mRNA export protein NXF2, in the mouse brain and testes. In this study, the team used mouse neuronal cells to explore the functional characteristics of this interaction.

We found that FMRP, together with NXF2, acts to down-regulate the expression of its target, the messenger RNA that encodes NXF1, which is an essential protein needed to transport most mRNAs from the nucleus to the cytoplasm of cells, said Huang. Our findings explain why the NXF1 protein level is much lower in the hippocampal neurons involved in learning and memory than in many other cells. This may suggest that a high level of NXF1 might hinder the function of these cells.

We are one of the first two labs to show that FMRP regulates gene expression at the mRNA stability level, Huang added. The idea is to find the mechanisms underlying the function of FMRP so in the future, we can develop more effective interventions.

Huang said future studies will look more clo sely at how FMRP works with NXF2 to regulate its targets. She said, We expect to identify more targets which are regulated by FMRP and NXF2. This will be a new direction in the FMRP research field.


'"/>




Related medicine news :

1. Latest Findings On The Deadly Disease - SARS
2. New Findings Could Reduce The Extent Of Spinal Cord Injuries
3. New Findings for Repeated Miscarriages
4. How Healthy Are Herbal Products? US Findings.
5. Dispute in Findings about Radiation exposure
6. New Findings on Autism Research
7. Engineering Nutrient-Rich Plants Made For Feasible By New Findings
8. Study Findings Could Help In Developing A Better Drug Delivery System
9. Findings Suggest New Method to Fight Staph Infections
10. Most Suicide Rates Decline, but Findings Are Puzzling
11. Arimidex-Herceptin Combo Therapy For Breast Cancer-Clinical Trial Findings
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2016)... ... February 09, 2016 , ... Ross A. Clevens, MD, ... to welcome a new addition to their growing practice. Beginning this month, Teresa ... nurse practitioner performing cosmetic procedures including injectables, fillers and laser treatments. ...
(Date:2/9/2016)... ... February 09, 2016 , ... Steven Douglas Associates is a ... Florida Event, an upscale fundraiser held in South Florida. The Inaugural What’s Your Taste ... This year the event will be held in a new, more causal format at ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... production of its newest mobility device, the StandUp Walker. Made entirely in the ... in the last 50 years. , StandUp Walker’s novel patent-pending design offers 2-in-1 ...
(Date:2/9/2016)... Springs, FL (PRWEB) , ... February 09, 2016 ... ... leading innovative specialty pharmacies, announces today the continuation of the ‘Pay It Forward’ ... for each prescription referral received at our specialty pharmacy. , “Since our ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Bon-Ton Stores, Inc. (NASDAQ: ... stores, announced it has raised $176,000 to benefit the Breast Cancer Research Foundation, ... at the University of Iowa, The Lynn Sage Cancer Research Foundation, and Masonic ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 9, 2016 On ... Administration (FDA) met with its Arthritis Advisory ... biosimilar of Johnson & Johnson,s Remicade and ... approved in the U.S. The Biologics Prescribers ... groups - Alliance for Patient Access, American ...
(Date:2/9/2016)... Calif. , Feb. 9, 2016 /PRNewswire/ - Nevro ... company that is providing innovative evidence-based solutions for the ... release financial results for the fourth quarter and full ... 29, 2016. Company management will host a conference call ... Time) on Monday, February 29, 2016. www.nevro.com ...
(Date:2/9/2016)... 9, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... today reported its fourth quarter and full year ... vivo therapeutic genome editing," said Edward Lanphier, ... finger nuclease (ZFN) technology leads the therapeutic genome ... competencies necessary to move our ground-breaking genome editing ...
Breaking Medicine Technology: